NASDAQ:BRTX Biorestorative Therapies Q1 2026 Earnings Results & Report $1.50 -0.09 (-5.66%) Closing price 10/14/2026 03:58 PM EasternExtended Trading$1.45 -0.05 (-3.60%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Biorestorative Therapies beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$3.80 versus the -$4.00 consensus estimate, while revenue of $0.02 million fell short of the $0.31 million estimate by $0.29 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market OpensConference Call4:00 PM ET Biorestorative Therapies EPS ResultsActual EPS-$3.80Consensus EPS -$4.00Beat/MissBeat by +$0.20One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersBiorestorative Therapies Revenue ResultsActual Revenue$0.02 millionExpected Revenue$0.31 millionBeat/MissMissed by -$288.83 thousandYoY Revenue GrowthN/AUpcoming EarningsBiorestorative Therapies' Q2 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Biorestorative Therapies Q1 2026 Earnings FAQ Did Biorestorative Therapies beat earnings estimates for Q1 2026? Biorestorative Therapies (NASDAQ:BRTX) reported earnings of -$3.80 per share for Q1 2026, beating the consensus estimate of -$4.00. The report was announced on Thursday, May 14, 2026. What was Biorestorative Therapies' revenue for Q1 2026? Biorestorative Therapies reported revenue of $0.02 million for Q1 2026, against a consensus estimate of $0.31 million. When is Biorestorative Therapies' next earnings date? Biorestorative Therapies' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Biorestorative Therapies on the company's earnings history page. Biorestorative Therapies Earnings HeadlinesMaxim Group downgrades BioRestorative Therapies to hold from buyOctober 6, 2026 | msn.comMaxim Downgrades BioRestorative Therapies to Hold From BuyOctober 6, 2026 | marketscreener.comMSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 15 at 1:00 AM | Altimetry (Ad)Biorestorative Therapies (NASDAQ:BRTX) Stock Rating Lowered by Maxim GroupOctober 6, 2026 | americanbankingnews.comBioRestorative Therapies (BRTX)September 29, 2026 | es.investing.comBioRestorative Therapies consensus price target increased by 1,900% to $163.20September 16, 2026 | msn.comSee More Biorestorative Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email. Email Address About Biorestorative TherapiesBiorestorative Therapies (NASDAQ:BRTX) (NASDAQ:BRTX) is a development-stage biotechnology company focused on regenerative medicine and cell-based therapies. The company’s programs are designed to use adult stem cells and related biological materials to address conditions for which existing treatment options may be limited. Its lead program, BRTX-100, is an autologous cell therapy derived from a patient’s own bone marrow. The product is being developed for the treatment of painful chronic lower-back conditions associated with degenerative discs. BioRestorative Therapies has also developed proprietary processes for collecting, processing and cryopreserving cellular material for potential therapeutic use. The company’s other principal program, ThermoStem, is focused on the potential use of brown adipose-derived stem cells in treating obesity and related metabolic disorders. BioRestorative Therapies is headquartered in the United States and conducts its development activities through research, clinical and regulatory programs. As a biotechnology company, its products remain subject to clinical development and regulatory review before they can be broadly commercialized.View Biorestorative Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenUnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
